Disease modifying effect of statins in dextran sulfate sodium model of mouse colitis

Inflammation Research

Volumn 57, Issue 1, 2008, Pages 34-38

  Kanagarajan, N ^a   Nam, J H ^a   Al Noah, Z ^b   Murthy, S ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

Atorvastatin; Colitis; Dextran Sodium Sulfate (DSS); Simvastatin; Statins

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A1 ANTIBODY; ATORVASTATIN; DEXTRAN SULFATE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHYLCELLULOSE; PROTEIN ANTIBODY; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLITIS; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; FEMALE; NONHUMAN; OCCULT BLOOD;

ANIMALS; APOLIPOPROTEIN A-I; COLITIS; COLON; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; FEMALE; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, HDL; MICE; OCCULT BLOOD; PYRROLES; SIMVASTATIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 38349145438     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-007-6177-4     Document Type: Article

References (20)

1. Wierzbecki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacology & Therapeutics 2003; 99: 95-112.
2. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E: Long-term effects of pravastatin on plasma concentrations of C-reactive protein. Circulation 1999; 100: 230-5.
3. Zhao SP, Zhang DQ: Atorvastatin reduces interleukin-6 plasma concentration and adipocyte secretion of hypercholesterolemic rabbits. Clin Chim Acta 2003; 336: 103-8.
4. Hakamada-Taguchi R, Uehara Y, Kuribayashi K, Numabe A, Saito K, Negoro H et al. Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development. Circ Res 2003; 93: 948-56.
5. Murthy S, Cooper HS, Yositake H, Meyer C, Meyer CJ, Murthy NS. Combination therapy of pentoxifylline and TNF-alpha monoclonal antibody in dextran sulphate-induced mouse colitis. Aliment Pharmacol Ther 1999; 13(2): 251-60.
6. Kojouharoff G, Hans W, Obermeier F, Mannel DN, Andus T, Scholmerich J et al. Neutralization of tumor necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice. Clin Exp Immunol 1997; 107(2): 353-8.
7. Murthy SN, Cooper HS, Shim H, Shah RS, Ibrahim SA, Sedergran DJ. Treatment of dextran sulphate sodium-induced murine colitis by intracolonic cyclosporine. Dig Dis Sci 1993; 38(9): 1722-34.
8. Murthy S, Murthy NS, Coppola D, Wood DL. The efficacy of BAY y 1015 in dextran sulfate model of mouse colitis. Inflamm Res 1997; 46(6): 224-33.
9. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's disease cA2 study group. New Engl J of Medicine 1997; 337 (15): 1029-35.
10. Cooper HS, Murthy SN, Shah RS, Sedergren DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993; 69 (2): 238-49.
11. Sparrow CP, Burton CA, Hernandez M, Mundt S, Hassing H, Patel S et al. Simvastatin has anti-inflammatory and anti-atherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 2001; 21(1): 115-21.
12. Lee JY, Kim JS, Kim JM, Kim N, Jung HC, Song IS. Simvastatin inhibits NF-kappaB signaling in intestinal epithelial cells and ameliorates acute murine colitis. Int Immunopharmacol 2007; 7(2): 241-8.
13. Saubermann LJ, Nakajima A, Wada K, Zhao S, Terauchi Y, Kadowaki T et al. Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis. Inflamm Bowel Dis 2002; 8(5): 330-9.
14. Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002; 420(6911): 78-84.
15. Murthy S, Flanigan A, Coppola D and Buelow R. RDP 58, a locally active TNF inhibitor, is effective in the dextran sulphate mouse model of chronic colitis. Inflamm Res 2002; 51(11); 522-31.
16. Lindsay JO, Sandison A, Cohen P, Brennan FM, Hodgson HJ. IL-10 gene therapy is therapeutic for dextran sodium sulfate-induced murine colitis. Dig Dis Sci 2004; 49(7-8): 1327-34.
17. Gotsman I, Shlomai A, Alper R, Rabbani E, Engelhardt D, Ilan Y. Amelioration of immune-mediated experimental colitis: tolerance induction in the presence of preexisting immunity and surrogate antigen bystander effect. J Pharmacol Exp Ther 2001; 297 (3): 926-32.
18. Rea WE, Durrant DC, Boldy DA. Ulcerative colitis after statin treatment. Postgrad Med J 2002; 78(919): 286-7.
19. Leung FW, Lieberman J, Fagen N, Kasimian D, Wick R. Colonoscopic features of simvastatin-induced colitis suggest ischemia as an etiologic mechanism. Gastrointest Endosc 2005; 62(1): 175-8.
20. Tomita R, Tanjoh K. Role of nitric oxide in the colon of patients with ulcerative colitis. World J Surg 1998; 22: 88-91.